DENTAL-MONITORING
Smile Doctors, the largest US based Orthodontic DSO (Dental Support Organization), with over 220 locations in 17 States, has signed a deal with Dental Monitoring to use its suite of AI powered remote monitoring solutions to provide industry leading patient access and convenience. Importantly, the original partnership agreed after several months of pilots and testing, has been expanded and accelerated to include all patients eligible with immediate effect this week, due to the Coronavirus national situation. All eligible Smile Doctors patients will therefore be able to start or continue their treatment remotely with Dental Monitoring.
Dental Monitoring will provide access to and training for all Smile Doctors specialist orthodontist clinics nationwide to all DM products, including SmileMate, Vision and Dental Monitoring.
- SmileMate enables virtual consultations with prospective new patients at home, offering an almost instant oral health assessment through photos taken with the patient’s own smartphone.
- Vision uses AI to produce within seconds an instant simulation of the patient’s face with different orthodontic appliances and also generates state-of-the-art simulation of post-treatment smiles, using the actual details of the patient’s teeth and gums, helping the patient choose their treatment with more confidence.
- Dental Monitoring uses AI to allow the Doctor to remotely monitor the progress of the patient’s treatment through photos taken by the patient using the DM app on their own smartphone, with a DM ScanBox. The Dental Monitoring solution allows real time communication between the Doctor’s team and the patient.
Commenting on the deal, CEO of Smile Doctors, J. Hedrick explained: “I am delighted to have achieved this partnership with Dental Monitoring, which I am certain will be to the extreme benefit to all of our patients. Dental Monitoring’s AI technology and patient user experience is second to none, and has brought dentistry up to speed with patients’ expectations in a digital world. The initial reception by both clinical team and patients in our pilots has been extremely positive, and we believe we have a unique differentiator in our offering to our Smile Doctors patients.”
CEO and Co-Founder of Dental Monitoring, Philippe Salah, added: “Smile Doctors for us is the ideal partner as we accelerate our growth in the US. We have established a true partnership where we will help Smile Doctors to fully utilize the full suite of DM products. We enable their orthodontists to address the needs of new patients, allow more of them to say yes to treatment, and then monitor their treatment progress efficiently, using our DM proprietary AI engine.”
On the acceleration of the partnership due to the current Coronavirus crisis, J. Hedrick said: “We decided to fast track our implementation of DM full heartedly throughout our entire network to make sure we could continue to serve our patients with the best clinical care. Dental Monitoring has been a unique and essential partner for us, and we are excited to be rolling out this service at such speed to respond to the crisis. I am grateful to Philippe and the DM team for really working side by side with us on this 24/7 in the interests of our patients.”
About Dental Monitoring (www.dental-monitoring.com )
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney. For more information, please visit www.dental-monitoring.com .
About Smile Doctors, LLC ( www.smiledoctors.com )
Smile Doctors, LLC is the largest orthodontic dental support organization with more than 200 affiliated practices in 17 states. Based in Georgetown, TX and founded by Dr. Scott Law, Scotte Hudsmith, Dr. Dana Fender, and Dr. Greg Goggans, Smile Doctors focuses exclusively on developing and growing affiliated orthodontic practices. Orthodontists can focus on patient care while receiving the support of experienced professionals who are committed to the growth and success of their practices. Support provided by Smile Doctors includes services related to operations, accounting, marketing, and revenue cycle. For more information, please visit www.smiledoctors.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005353/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 08:30:00 CET | Press release
The GDC, established in LTTS’ Mobility segment, will strengthen PALFINGER’s localization roadmap and next-gen digital transformation initiatives L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, E
New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 08:10:00 CET | Press release
Cinemo and Futuresource Consulting’s research indicates consumer readiness for integrated audio environments, accelerating the shift from connected devices to a connected lifestyle. Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
